Biotransformation

BioIVT to Showcase Leading Products for Toxicological Studies at the SOT ToxExpo 2024

Retrieved on: 
Thursday, March 7, 2024
Metabolism, SOT, Doctor of Philosophy, Research, Prodrug, Drug development, DDI, Society of Toxicology, Hall, Immune system, Learning, Cell, Poster, CES, Biotransformation, ADME, Medical device

WESTBURY, N.Y., March 7, 2024 /PRNewswire/ -- BioIVT , a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced its presence and scientific contributions at the 2024 Society of Toxicology (SOT) 63rd Annual Meeting and ToxExpo .

Key Points: 
  • WESTBURY, N.Y., March 7, 2024 /PRNewswire/ -- BioIVT , a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced its presence and scientific contributions at the 2024 Society of Toxicology (SOT) 63rd Annual Meeting and ToxExpo .
  • "The BioIVT team attending SOT includes experts from across our product portfolios.
  • We look forward to meeting with research colleagues and learning how we can support their programs," he added.
  • Visit BioIVT on the show floor at booth #1509 or schedule a time to connect with us and learn more: https://bioivt.com/about/events?entry=SOT+ToxExpo+2024

IDTechEx Discusses the Technology Trends Driving Sustainable Polymers for a Circular Economy

Retrieved on: 
Tuesday, November 14, 2023
Carbon, Suntory, Pressure, Research, Biomass, CCU, MEG, Plant, TPA, Carbon dioxide, Recycling, OECD, PLA, Investment, Government, PEF, Mitsubishi Corporation, Polymer, CO2, Polyhydroxyalkanoates, Biotechnology, Fungus, Bankruptcy, Neste, Lobbying, Biotransformation, Dissolution, BASF, Polyethylene, Lactic acid, Bacteria, Eneos, Synthetic biology, Traction, ExxonMobil, Non-governmental organization, Growth, Eastman Chemical Company, PET, PHA, Environment, United Nations, Renewable energy, Coal, Fine chemical, Plastic, Players, Covestro

Answering this demand for more sustainable plastics to support the circular economy requires innovations from all stakeholders in the polymer value chain, from the chemical suppliers to the end-users to the recyclers.

Key Points: 
  • Answering this demand for more sustainable plastics to support the circular economy requires innovations from all stakeholders in the polymer value chain, from the chemical suppliers to the end-users to the recyclers.
  • Lastly, the end-of-life recycling of these plastics, through both well-established mechanical recycling and the more emerging advanced recycling , is critical to establishing a truly circular economy.
  • In this article, IDTechEx considers some of the technology developments, challenges, and the outlook of the innovations affecting each part of the polymer value chain.
  • IDTechEx will be hosting a free-to-attend webinar on the topic on Tuesday 21 November 2023 - Creating a Circular Economy: Emerging Sustainable Materials to Watch in 2024 .

IDTechEx Discusses the Technology Trends Driving Sustainable Polymers for a Circular Economy

Retrieved on: 
Tuesday, November 14, 2023
Carbon, Suntory, Pressure, Research, Biomass, CCU, MEG, Plant, TPA, Carbon dioxide, Recycling, OECD, PLA, Investment, Government, PEF, Mitsubishi Corporation, Polymer, CO2, Polyhydroxyalkanoates, Biotechnology, Fungus, Bankruptcy, Neste, Lobbying, Biotransformation, Dissolution, BASF, Polyethylene, Lactic acid, Bacteria, Eneos, Synthetic biology, Traction, ExxonMobil, Non-governmental organization, Growth, Eastman Chemical Company, PET, PHA, Environment, United Nations, Renewable energy, Coal, Fine chemical, Plastic, Players, Covestro

Answering this demand for more sustainable plastics to support the circular economy requires innovations from all stakeholders in the polymer value chain, from the chemical suppliers to the end-users to the recyclers.

Key Points: 
  • Answering this demand for more sustainable plastics to support the circular economy requires innovations from all stakeholders in the polymer value chain, from the chemical suppliers to the end-users to the recyclers.
  • Lastly, the end-of-life recycling of these plastics, through both well-established mechanical recycling and the more emerging advanced recycling , is critical to establishing a truly circular economy.
  • In this article, IDTechEx considers some of the technology developments, challenges, and the outlook of the innovations affecting each part of the polymer value chain.
  • IDTechEx will be hosting a free-to-attend webinar on the topic on Tuesday 21 November 2023 - Creating a Circular Economy: Emerging Sustainable Materials to Watch in 2024 .

EQS-News: Capital Markets Day 2023: BRAIN Biotech AG to build an international multi-niche enzyme and food ingredients champion

Retrieved on: 
Monday, February 27, 2023
Bioproduct, EBITDA, Social, Food, Capital market, Business, Genomics, M-Brain Group, Gedit, CMD, BioScience, BRAIN, Enzyme, Growth, Environment, Drink, CFO, Fermentation, Health, Biotransformation, Renewable energy, Fine chemical

Zwingenberg, Germany, 27 February 2023 – BRAIN Biotech AG, a leading provider of integrated solutions for the biologization of industry, has today at its fourth Capital Markets Day (CMD) informed investors about its future strategy.

Key Points: 
  • Zwingenberg, Germany, 27 February 2023 – BRAIN Biotech AG, a leading provider of integrated solutions for the biologization of industry, has today at its fourth Capital Markets Day (CMD) informed investors about its future strategy.
  • Creating an international multi-niche enzyme and food ingredients champion builds the core of BRAIN Biotech’s future growth strategy.
  • Now we have a solid base to build out our strategy of profitable growth with the aim to build an international multi-niche enzyme champion.
  • The BioIncubator contains BRAIN Biotech’s breakthrough discovery projects and the product pipeline to build the future in biotech, including Akribion Genomics.

Global Biotech Flavor Market Report to 2027: Need to Reduce Sodium and Sweet Content Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 10, 2023
Food Tech, Retail, Health, Technology, Food, Beverage, Biotechnology, OECD, Drink, Biotechnology, Biotransformation, Bioreactor, Health, Sodium, Energy drink, Growth, Diet, Panic, COVID 19, COVID-19, Food, Fine chemical, Beer

The "Biotech Flavor Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Biotech Flavor Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering.
  • The global biotech flavor market is expected to grow at a compound annual growth rate of 6.61% over the forecast period to reach a market size of US$3.337 billion in 2027, from US$2.132 billion in 2020.
  • There have been certain strategic initiatives by various players in the biotech flavour market space in recent years.
  • Increasing trends in product reformulations that are being made compulsory by various regulatory measures like the need to reduce sodium and sweet content are also expected to propel the growth of the biotech flavour market.

GenScript Partners with Allozymes to Accelerate Protein Discovery and Target Identification

Retrieved on: 
Wednesday, December 7, 2022
Biotechnology, Heart, Enzyme, Food, Protein engineering, GenScript Biotech, CDMO, Patent, Doctor of Philosophy, Metabolic engineering, Partnership, Synthetic biology, Cosmetics, Biotransformation, Growth, SEA, Biochemistry, Hong Kong Stock Exchange, University, Fine chemical, Alloenzyme

PISCATAWAY, N.J., Dec. 7, 2022 /PRNewswire/ -- GenScript Biotech Corporation, the world's leading provider of life-science research tools and services, is partnering with Allozymes, a Singapore-based biotech startup, to dramatically accelerate the enzyme discovery and development process. GenScript will provide the mutant libraries construction and expression, while Allozymes will provide ultra-high-throughput screening service for applications across various industries, including pharmaceuticals, cosmetics, and food and beverage.

Key Points: 
  • PISCATAWAY, N.J., Dec. 7, 2022 /PRNewswire/ -- GenScript Biotech Corporation , the world's leading provider of life-science research tools and services, is partnering with Allozymes , a Singapore-based biotech startup, to dramatically accelerate the enzyme discovery and development process.
  • Allozymes is a deep-tech company that is transforming ingredient manufacturing by unlocking the protein engineering potential through groundbreaking technologies.
  • "We are grateful for Allozymes' trust in GenScript to bring our partnership to a higher level, and we are delighted to join forces to help researchers accelerate their enzyme and protein research.
  • Allozymes is accelerating the development of biosolutions and shortening time to market for its partners by 10x.

Full Day Virtual Seminar on Fundamentals of Pharmacokinetics - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 9, 2022
Health, General Health, Risk, Drug discovery, Failure, Learning, PD, Absorption, Knowledge, Urine, Bile, Knowledge management, Biotransformation, Drug development, Decision-making, Element, PK, Kidney, Pharmacokinetics, Metabolism, Generic drug, Civil engineering

The "Full Day Virtual Seminar on Fundamentals of Pharmacokinetics" webinar has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Full Day Virtual Seminar on Fundamentals of Pharmacokinetics" webinar has been added to ResearchAndMarkets.com's offering.
  • This course assumes no prior PK knowledge and aims to give you a broad understanding of this fascinating subject, using multiple case studies and relevant examples.
  • You will learn what pharmacokinetics involves, what data is collected, and its impact on the drug development process.
  • To get a better understanding of the different aspects that contribute to the pharmacokinetic profile of a new chemical entity.

Chung-Ang University Study Reports Hepatic Toxicity from Endocrine Disrupting Chemical Mixtures

Retrieved on: 
Friday, August 5, 2022
Liver, Ministry of Food and Drug Safety, Risk, Combined, Gene, Mouse, Oxidative stress, Hormone, Plastic, Non-alcoholic fatty liver disease, Cosmetics, Urine, Male, EDC, Cirrhosis, Liver injury, DE, Biotransformation, Ministry, BPA, Infection, Chung-Ang University, Hepatitis, Cholesterol, Journal, Immune system, Cell death, Bouquet (EP), Manifest and latent functions and dysfunctions, Perfume, Steatohepatitis, Food

Bisphenol A (BPA) and phthalates, which are widely used in consumer products including plastics, aluminum cans, pharmaceuticals, and cosmetics, are well-known EDCs.

Key Points: 
  • Bisphenol A (BPA) and phthalates, which are widely used in consumer products including plastics, aluminum cans, pharmaceuticals, and cosmetics, are well-known EDCs.
  • Since both BPA and phthalates are structurally similar to steroid hormones that regulate chemical signaling in the body, they are capable of manipulating and disrupting hormonal functions.
  • Studies involving animal models and human urine samples have confirmed the positive correlation between exposure to individual EDCs and abnormal liver function.
  • "Our study tried to change the conventional toxicological approach and we hope it has an enormous impact on regulatory and public health perspectives," says Prof. Pang.

Bruker is Ushering in the Age of Spatial Single-Cell Metabolomics

Retrieved on: 
Tuesday, June 21, 2022
Science, Other Science, Research, Solution, Metabolomics, MALDI, Molecular Medicine Partnership Unit, Therapy, Microgrid, Bruker, EMBL, Institute of Liver and Biliary Sciences, Tissue, Ageing, Technology, International Conference on Systems Biology, Regenerative medicine, Artifact, Precision medicine, Molecular medicine, Biotransformation, Proteomics, Cancer, Research, Isotope, Drug discovery, Algorithm, Microscopy, CCS, Nasdaq, Conference, Flex, Cell biology, Life, Microscope, Medical imaging

At the 18th International Conference of the Metabolomics Society, Bruker Corporation (Nasdaq: BRKR) announced key innovations for spatial multiomics with a focus on unbiased Spatial Single-Cell Metabolomics (SSCM) for probing differential cellular phenotypes based on the metabolic signature of tissues and single cells.

Key Points: 
  • At the 18th International Conference of the Metabolomics Society, Bruker Corporation (Nasdaq: BRKR) announced key innovations for spatial multiomics with a focus on unbiased Spatial Single-Cell Metabolomics (SSCM) for probing differential cellular phenotypes based on the metabolic signature of tissues and single cells.
  • Dr. Alexandrov commented: We are in the process of developing the SpaceM technology for spatial single-cell metabolomics, developed at EMBL Heidelberg, into a platform for rapid drug discovery.
  • In addition, the latest microGRID technology will provide us with the high spatial resolution needed to precisely interrogate single cells.
  • Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life.

LifeMine Therapeutics Announces $175 Million Series C Financing

Retrieved on: 
Wednesday, March 23, 2022
Science, Other Science, Biotechnology, Pharmaceutical, Finance, Health, Professional Services, Genetics, Company, GEM, Therapy, GSK, Synthetic biology, Data science, Gemstone, Partners Capital, Cancer, Stage Fort across Gloucester Harbor, Biotransformation, Artificial intelligence, GV, Drug discovery, Pharmaceutical industry, GlaxoSmithKline

LifeMine Therapeutics Inc., a biopharmaceutical company reinventing drug discovery by mining genetically-encoded small molecules (GEMs) from the biosphere, today announced the completion of a $175 million Series C financing.

Key Points: 
  • LifeMine Therapeutics Inc., a biopharmaceutical company reinventing drug discovery by mining genetically-encoded small molecules (GEMs) from the biosphere, today announced the completion of a $175 million Series C financing.
  • Proceeds from the financing will be used to advance LifeMines proprietary, evolutionarily-derived genomic drug discovery platform, Avatar-Rx.
  • LifeMine Therapeutics is reinventing drug discovery by mining genetically-encoded small molecules (GEMs) from the biosphere.
  • Headquartered in Cambridge, Mass., and with a second site at Gloucester Harbor, Mass., LifeMine has raised more than $295 million from leading life science investors.